Physician profile
Kavin Arasar
NPI 1386030153
$13,195.34
in general payments reported to CMS, 2019-2025
34 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $103 · 2021: $1,016 · 2022: $6,346 · 2023: $1,282 · 2024: $2,656 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,532.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,289.75 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,062.43 | 2021-2025 | |
| Abiomed | $992.72 | 2021-2025 | Impella |
| Cardiovascular Systems INC. | $841.59 | 2019-2023 | Diamondback Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $733.18 | 2019-2025 | Lifevest |
| Abbott Laboratories | $705.01 | 2021-2025 | Coroflow, Cardiomems, Xience Skypoint |
| Inari Medical, INC. | $519.49 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $434.32 | 2021-2025 | Farxiga |
| Boston Scientific Corporation | $409.48 | 2021-2025 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $387.87 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.43 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $299.30 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $283.17 | 2023-2025 | Repatha, Repatha |
| Heartflow, INC. | $222.59 | 2024-2025 | |
| Acist Medical Systems, INC. | $207.25 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $193.43 | 2019-2025 | |
| Shockwave Medical, INC | $154.72 | 2021-2022 | |
| Penumbra, INC. | $148.96 | 2022 | |
| Esperion Therapeutics, INC. | $105.49 | 2024-2025 | Nexletol |
| Novo Nordisk INC | $105.20 | 2024-2025 | Ozempic, Wegovy |
| W. L. Gore & Associates, INC. | $100.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $88.71 | 2021 | |
| Merck Sharp & Dohme LLC | $85.70 | 2023-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $82.91 | 2024 | |
| Kestra Medical Technology Services, INC. | $76.65 | 2023-2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $54.57 | 2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $45.59 | 2023-2024 | Uptravi, Opsumit |
| Cathworks, INC. | $44.96 | 2022 | |
| Terumo Medical Corporation | $43.75 | 2023 | Glidewire, Heartrail |
| Edwards Lifesciences Corporation | $29.03 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $22.15 | 2025 | Zepbound, Mounjaro |
| Baxter Healthcare | $21.36 | 2024 | Biopharma Sol - Contract Manuf |
| Scpharmaceuticals INC. | $17.96 | 2024 | |
| Surmodics, INC. | $3.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavin Arasar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.